Related Experiment Video
Updated: Aug 9, 2026
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Management of metastatic melanoma 2005
1Department of Medicine, Keck School of Medicine, University of Southern California, 1975 Zonal Avenue, KAM 500, Los Angeles, CA 90089-9034, USA. soday@cimg.org
Abstract:
The management of metastatic melanoma in 2005 remains a major clinical challenge. Multidisciplinary treatment planning and careful attention to sites of metastases, tumor biology, and comorbid conditions are critical to making the best clinical decisions for individual patients. No standard of care exists because no systemic therapies have yet shown efficacy in phase III trials. Single-agent or combination chemotherapy has not impacted over-all survival, and response rates are of short duration. High-dose IL-2 produces durable responses in a small subset (7%) of highly selected patients and has considerable toxicity and quality-of-life trade-offs. Biochemotherapy results in overall higher responses, but its impact on overall survival has been disappointing and its toxicity and expense are considerable. Re-searchers are further investigating biochemotherapy modifications with maintenance biotherapy and CNS consolidation in effort to increase durability of responses and prevent or delay the devastating sequela of CNS metastases. Despite a disappointing past, the advancement of science and a better understanding of critical cellular targets and pathways make the future of melanoma research encouraging. Clinical trials are actively studying novel immune potentiators, cytotoxics, and targeted therapies. Combinations of these new agents will likely be necessary to advance the treatment of the dis-ease. All patients should be encouraged to participate in clinical trials.
Insights
Metastatic melanoma treatment in 2005 lacked a standard of care, with limited success from chemotherapy and biochemotherapy. Future melanoma research shows promise with novel therapies and clinical trials.
Area of Science:
- Oncology
- Dermatology
- Cancer Research
Background:
- Metastatic melanoma management in 2005 presented significant clinical challenges.
- No established standard of care existed due to lack of efficacy in phase III trials for systemic therapies.
Purpose of the Study:
- To review the state of metastatic melanoma treatment in 2005.
- To discuss current therapeutic options, their limitations, and future research directions.
Main Methods:
- Review of systemic therapies including chemotherapy, high-dose interleukin-2 (IL-2), and biochemotherapy.
- Discussion of treatment planning considerations: metastatic sites, tumor biology, and patient comorbidities.
- Exploration of ongoing research into novel agents and combination therapies.
Main Results:
- Chemotherapy showed no impact on overall survival with short-lived responses.
- High-dose IL-2 yielded durable responses in a small patient subset (7%) but with significant toxicity.
- Biochemotherapy offered higher response rates but disappointing overall survival, with considerable toxicity and cost.
Conclusions:
- Despite past challenges, advances in understanding melanoma biology offer encouraging future prospects.
- Novel immune potentiators, cytotoxics, and targeted therapies are under investigation.
- Combination therapies and clinical trial participation are crucial for advancing melanoma treatment.
